Toronto-based life sciences company ScarX Therapeutics Corp. reported that it has completed enrollment for the initial human clinical trial of its SCX-001 surgical scar reducing cream.
ScarX Therapeutics is currently conducting a Phase I clinical trial for SCX-001. This is a randomized, placebo-controlled, double-blind, and dose ranging study to evaluate the safety and tolerability of SCX-001 cream in healthy volunteers with induced dermal incisions.
The study is currently underway at the University of Alberta, Canada under the direction of Dr. Edward Tredget.
ScarX expects study results to become available in late 2017.
The company is calling its product a “first-of-its-kind topical treatment to significantly reduce surgical scarring.”
“ScarX Therapeutics is working to transform scar treatment and prevention,” said Stephen Whitehead, president, and CEO of the company. “Virtually everyone identifies with the need to minimize scarring and current treatment options are exceptionally limited.”
He said SCX-001 is a novel agent has the potential to help physicians heal wounds.
ScarX Therapeutics is a Toronto-based life sciences company founded in partnership with The Hospital for Sick Children and MaRS Innovation, which discovers and develops innovative treatments.
The company secured funding from Accel-Rx Health Sciences Accelerator, BDC Capital, MaRS Innovation and other investors.
Its lead product is intended to be the first topical prescription to treat and prevent post-surgical scarring, with the goal of better functional and cosmetic outcomes for patients.
The active ingredient in SCX-001 is a small molecule called nefopam, which has been reformulated as a proprietary cream specifically for dermal application.
Nefopam was first developed and commercialized in the late 1970’s as a non-narcotic analgesic drug in Europe, New Zealand and parts of Asia, according to ScarX.
SCX-001 is a nefopam topical cream that reduces the occurrence of scars following surgery.
Nefopam is a well-characterized small molecule that inhibits the production of β-catenin, the protein associated with hypertrophic (excessive) scarring in animals and humans.
“Beyond the palpable excitement from the clinical community and future patients, we are advancing discussions with potential partners and investors to further advance product development,” said Parimal Nathwani, executive chairman of ScarX Therapeutics and vice-president at MaRS Innovation, a founding investor.